torasemid hexal 10 mg tabletes
hexal ag, germany - torasemīds - tablete - 10 mg
torasemid hexal 10 mg tabletes
hexal ag, germany - torasemīds - tablete - 10 mg
convenia
zoetis belgium sa - cefovecin (as sodium salt) - antibakteriālie līdzekļi sistēmiskai lietošanai - dogs; cats - dogsfor ārstēšanu, ādas un mīksto audu infekcijas, tostarp pyoderma, brūces un abscesi, kas saistīti ar staphylococcus pseudintermedius, β hemolītiskā streptokoku, escherichia coli un / vai pasteurella multocida. ar escherichia coli un / vai proteus spp. saistītu urīnceļu infekciju ārstēšanai. kā papildu ārstēšana ar mehānisko vai ķirurģisko periodontoloģisko terapiju, ārstējot nopietnas porphyromonas spp. saistītās dandāras un periodontālas audu infekcijas. un prevotella spp. catsfor ārstēšanu, ādas un mīksto audu abscesi un brūces, kas saistīti ar pasteurella multocida, usobacterium spp. , bacteroides spp. , prevotella oralis, β-hemolītiskās streptokoku un / vai staphylococcus pseudintermedius. ar escherichia coli saistītu urīnceļu infekciju ārstēšanai.
torasemide teva 10 mg tabletes
teva pharma b.v., netherlands - torasemīds - tablete - 10 mg
torasemide teva 5 mg tabletes
teva pharma b.v., netherlands - torasemīds - tablete - 5 mg
torasemida teva 5 mg tabletes, efg
teva pharma s.l.u., spain - torasemīds - tablete - 5 mg
torasemida teva 10 mg tabletes, efg
teva pharma s.l.u., spain - torasemīds - tablete - 10 mg
torasemida teva 10 mg tabletes, efg
teva pharma s.l.u., spain - torasemīds - tablete - 10 mg
torasemida teva 5 mg tabletes, efg
teva pharma s.l.u., spain - torasemīds - tablete - 5 mg
nordimet
nordic group b.v. - metotreksāts - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastiski līdzekļi - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.